Citizens Raises Precigen Price Target Following Q3 Results
Following Precigen's third-quarter earnings beat, Citizens maintained its 'Market Outperform' rating and increased its price target for the company's stock.
Stocks · News reference
Precigen Shares Decline Following Approval of Rival RRP Treatment
Precigen's stock experienced significant downward pressure in premarket trading on November 2, 2026, following the FDA approval of a competing therapy for recurrent respiratory papillomatosis (RRP).
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Maintains Market Outperform on Precigen, Raises Price Target to $12
8-K filing — PRECIGEN, INC. (PGEN)
Filed: 2026-11-05 AccNo: 0000950103-26-016970 Size: 294 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Precigen Reports Third Quarter 2026 Financial Results
Precigen, Inc. announced its financial results for the third quarter of 2026, highlighting revenue growth from its PAPZIMEOS therapy and positive cash flow.
Precigen Q3 EPS $0.08 Beats $0.07 Estimate, Sales $74.148M Beat $71.558M Estimate
Precigen to Announce Third Quarter 2026 Financial Results on November 4
Precigen, Inc. announced it will release its financial results for the third quarter of 2026 and provide business updates on November 4, 2026.